Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of June 2015, specifically reporting on an event dated June 22, 2015. The filing serves as an English translation of an immediate report published on the Tel-Aviv Stock Exchange (TASE) and the Israeli Securities Authority (ISA). The company is a foreign private issuer filing under Form 20-F.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a corporate action report regarding capital structure changes.
Material Changes
The primary material change reported is an update to the company's securities count following the partial exercise of the underwriter's over-allotment option related to its initial public offering (IPO) in the U.S.
- Transaction: Allocation of 4,400,000 ordinary shares.
- Recipient: Bank Leumi Le-Israel Registration Company Ltd.
- Share Class: Ordinary shares with a par value of NIS 0.0000001 (TASE no. 1105204).
- Resulting Holdings: The total amount of securities held by the registration company is now 134,915,327.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or discussion of unusual items. It is a procedural notification of share allocation.
Investor Verification Checklist
- Verify the total outstanding share count post-allocation to confirm the 134,915,327 figure held by the registration company.
- Review the referenced immediate report dated June 21, 2015 (reference no. 2015-01-052110) for details on the initial IPO and the full over-allotment option terms.
- Confirm the ticker symbol and trading status on the TASE (TASE no. 1105204) following this capitalization update.